Pluristem Therapeutics (NASDAQ:PSTI)‘s stock had its “buy” rating reaffirmed by analysts at Maxim Group in a research note issued to investors on Wednesday, AnalystRatings.com reports. They presently have a $8.00 target price on the biotechnology company’s stock. Maxim Group’s price target points to a potential upside of 111.64% from the company’s previous close.
Several other equities analysts have also recently commented on PSTI. Zacks Investment Research raised shares of Pluristem Therapeutics from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a research report on Thursday, October 17th. HC Wainwright reiterated a “buy” rating and issued a $15.50 price target on shares of Pluristem Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $9.25.
PSTI stock traded down $0.02 during mid-day trading on Wednesday, hitting $3.78. 1,804 shares of the company were exchanged, compared to its average volume of 57,792. The firm has a fifty day simple moving average of $3.42 and a 200 day simple moving average of $2.71. Pluristem Therapeutics has a twelve month low of $3.11 and a twelve month high of $11.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.74 and a quick ratio of 2.74.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Featured Article: Market Timing – The Benefits and the Danger
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.